Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
#Partners #Investment
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
#Partners #Investment
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
#Public Trading
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
#Investment #Partners
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
#Customers #Investment
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
#Investment
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
undefined
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
undefined
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
#Investment #Expand
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
#Investment #Expand
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
undefined
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
#Investment #Expand
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
#Customers
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
#Investment
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
#Investment #Expand
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
#Customers
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
#Public Trading
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
#Management Changes
Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome
#Customers
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
#Customers
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
undefined
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
#Investment #Expand
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
undefined
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
undefined
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
undefined
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
undefined
Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate
#Customers
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
undefined
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
undefined
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
undefined
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
#Expand
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
undefined
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
undefined
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
#Customers
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update
undefined
Eloxx Pharmaceuticals Announces Changes to Board of Directors
undefined
Eloxx Pharmaceuticals Announces Changes to Board of Directors
#Management Changes
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
undefined
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
#Investment
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
#Acquisition #Management Changes
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis
#Customers
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019
#Expand
Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019
#Investment
Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019
#Investment
Eloxx Pharmaceuticals raises $50m on Nasdaq
#Investment #Management Changes
Biotech Company Eloxx Wants to Raise $50 Million on Nasdaq
#Public Trading
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million
#Investment #Acquisition #Public Trading
Eloxx Pharmaceuticals Raises US$6M in Funding - FinSMEs
#Investment #Acquisition #Public Trading
Eloxx Pharmaceuticals Raises US$24m in Series C Funding - FinSMEs
#Investment
http://www.marketwired.com/press-release/eloxx-pharmacueticals-receives-a-us5-million-investment-from-quark-venture-gf-securities-2220964.htm
undefined
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
undefined
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
#Investment